DUBLIN--(BUSINESS WIRE)--The \"Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026\" report has been added to ResearchAndMarkets.com's offering.<\/p>\n
Global Recombinant Plasma Protein Therapeutics Market: Overview<\/p>\n
This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.<\/p>\n
The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.<\/p>\n
New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)<\/p>\n
Key Topics Covered: <\/p>\n
1. Preface <\/p>\n
1.1. Market Definition and Scope<\/p>\n
1.2. Market Segmentation<\/p>\n
1.3. Key Research Objectives<\/p>\n
1.4. Research Highlights<\/p>\n
2. Assumptions and Research Methodology <\/p>\n
3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market <\/p>\n
4. Market Overview <\/p>\n
4.1. Introduction<\/p>\n
4.1.1. Product Definition<\/p>\n
4.1.2. Industry Evolution\/Developments<\/p>\n
4.2. Overview<\/p>\n
4.3. Market Dynamics<\/p>\n
4.3.1. Drivers<\/p>\n
4.3.2. Restraints<\/p>\n
4.3.3. Opportunities<\/p>\n
4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016-2026<\/p>\n
5. Key Insights <\/p>\n
5.1. New Product Launch and Regulatory Approvals<\/p>\n
5.2. Key Mergers & Acquisitions<\/p>\n
5.3. Regulatory Scenario by Region\/Country<\/p>\n
6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class <\/p>\n
6.1. Introduction & Definition<\/p>\n
6.2. Key Findings\/Developments<\/p>\n
6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class<\/p>\n
7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line <\/p>\n
7.1. Introduction & Definition<\/p>\n
7.2. Key Findings\/Developments<\/p>\n
7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line<\/p>\n
8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication <\/p>\n
8.1. Introduction & Definition<\/p>\n
8.2. Key Findings\/Developments<\/p>\n
8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication<\/p>\n
9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region <\/p>\n
9.1. Key Findings<\/p>\n
9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region<\/p>\n
9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region<\/p>\n
10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast <\/p>\n
10.1. Introduction<\/p>\n
10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016-2026<\/p>\n
10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis<\/p>\n
11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast <\/p>\n
11.1. Introduction<\/p>\n
11.1.1. Key Findings<\/p>\n
11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country\/Sub-region, 2016-2026<\/p>\n
11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis<\/p>\n
12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast <\/p>\n
12.1. Introduction<\/p>\n
12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country\/Sub-region, 2016-2026<\/p>\n
12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis<\/p>\n
13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast <\/p>\n
13.1. Introduction<\/p>\n
13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country\/Sub-region, 2016-2026<\/p>\n
13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis<\/p>\n
14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast <\/p>\n
14.1. Introduction<\/p>\n
14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026<\/p>\n
14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026<\/p>\n
14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026<\/p>\n
14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country\/Sub-region, 2016-2026<\/p>\n
14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis<\/p>\n
15. Competitive Landscape <\/p>\n
15.1. Market Player - Competition Matrix (By Tier and Size of companies)<\/p>\n
15.2. Market Share Analysis By Company (2016)<\/p>\n
15.3. Company Profiles<\/p>\n
15.3.1. CSL Limited<\/p>\n
15.3.2. Shire (Takeda Pharmaceutical Company Limited)<\/p>\n
15.3.3. Octapharma<\/p>\n
15.3.4. Novo Nordisk A\/S<\/p>\n
15.3.5. Bayer AG<\/p>\n
15.3.6. Pfizer Inc.<\/p>\n
15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)<\/p>\n
15.3.8. Aptevo Therapeutics<\/p>\n
15.3.9. Pharming Group NV<\/p>\n
For more information about this report visit https:\/\/www.researchandmarkets.com\/r\/4aj3c2<\/a><\/p>\n<\/p>\n <\/p>\n Read more here: DUBLIN--(BUSINESS WIRE)--The \"Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026\" report has been added to ResearchAndMarkets.com's offering. Global Recombinant Plasma Protein Therapeutics Market: Overview This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Continue reading
\nGlobal Recombinant Plasma Protein Therapeutics Market - Industry Analysis, Size, Share, Growth, Trends & Forecast 2018-2026 -...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"